Development and validation of a risk-score model for subjects with impaired glucose tolerance for the assessment of the risk of type 2 diabetes mellitus-The STOP-NIDDM risk-score

Diabetes Research and Clinical Practice

Volumn 87, Issue 2, 2010, Pages 267-274

  Tuomilehto, Jaakko ^a,b,c   Lindström, Jaana ^a,b   Hellmich, Martin ^d   Lehmacher, Walter ^d   Westermeier, Torsten ^e   Evers, Thomas ^e   Brückner, Andreas ^f   Peltonen, Markku ^b   Qiao, Qing ^a   Chiasson, Jean Louis ^g  

^a UNIVERSITY OF HELSINKI   (Finland)

^b NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^c SOUTH OSTROBOTHNIA CENTRAL HOSPITAL   (Finland)

^d UNIVERSITY OF COLOGNE   (Germany)

^e BAYER AG   (Germany)

^f BAYER PHARMA AG   (Germany)

^g Centre Hospitalier   (Canada)

Author keywords

Glucose tolerance; Risk score; Type 2 diabetes

Indexed keywords

ACARBOSE; GLUCOSE; PLACEBO; TRIACYLGLYCEROL;

ADULT; AGED; ANAMNESIS; ARTICLE; BODY HEIGHT; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; HIGH RISK PATIENT; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROCESS DEVELOPMENT; RANDOMIZED CONTROLLED TRIAL; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; SCORING SYSTEM; STATISTICAL MODEL; STUDY TO PREVENT NON INSULIN DEPENDENT DIABETES MELLITUS; TRIACYLGLYCEROL BLOOD LEVEL; VALIDATION PROCESS; WAIST CIRCUMFERENCE;

ADULT; AGED; BODY MASS INDEX; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; GLUCOSE INTOLERANCE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; RISK FACTORS; TRIGLYCERIDES; WAIST CIRCUMFERENCE;

EID: 74449086273     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2009.11.011     Document Type: Article

References (46)

1. International Diabetes Federation, Diabetes Atlas, Available at: http://www.eatlas.idf.org (accessed April 2006).
2. Zimmet P. The burden of type 2 diabetes: are we doing enough?. Diabetes Metab. 29 (2003) S9-S18
3. Engelgau M.M., Colagiuri S., Ramachandran A., Borch-Johnsen K., and Narayan K.M. Prevention of type 2 diabetes: issues and strategies for identifying persons for interventions. Diabetes Technol. Ther. 6 (2004) 874-882
4. Conroy R.M., Pyorala K., Fitzgerald A.P., Sans S., Menotti A., De Backer G., et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur. Heart J. 24 (2003) 987-1003
5. Assmann G., Cullen P., and Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study. Circulation 105 (2002) 310-315
6. Jackson R. Updated New Zealand cardiovascular disease risk-benefit prediction guide. Br. Med. J. 320 (2000) 709-710
7. Anderson K.M., Odell P.M., Wilson P.W., and Kannel W.P. Cardiovascular disease risk profiles. Am. Heart J. 121 (1991) 293-298
8. Wilson P.W., D'Agostino R., Levy D., Belanger A., Silbershatz H., and Kannel W. Prediction of coronary heart disease using risk factor categories. Circulation 97 (1998) 1837-1847
9. Kivipelto M., Ngandu T., Laatikainen T., Winblad B., Soininen H., and Tuomilehto J. Risk score for the prediction of dementia risk in 20 years among middle aged people: a longitudinal, population-based study. Lancet Neurol. 5 (2006) 735-741
10. de Vegt F., Dekker J.M., Jager A., Hienkens E., Kostense P.J., Stehouwer C.D., et al. Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population: the Hoorn Study. JAMA 285 (2001) 2109-2113
11. Qiao Q., Lindström J., Valle T.T., and Tuomilehto J. Progression to clinically diagnosed and treated diabetes from impaired glucose tolerance and impaired fasting glycaemia. Diabet. Med. 20 (2003) 1027-1033
12. Tuomilehto J., and Lindström J. The major diabetes prevention trials. Curr. Diab. Rep. 3 (2003) 115-122
13. Simpson R.W., Tuomilehto J., Lindström J., Shaw J.E., and Zimmet P. Prevention of type 2 diabetes mellitus. In: DeFronzo R., Ferrannini E., Keen H., and Zimmet P. (Eds). International Textbook of Diabetes Mellitus. third edition (2004), John Wiley & Sons Ltd. 1899-1913
14. Stern M.P., Williams K., and Haffner S.M. Identification of persons at high risk for type 2 diabetes mellitus: do we need the oral glucose tolerance test?. Ann. Intern. Med. 136 (2002) 575-581
15. Lindström J., and Tuomilehto J. The diabetes risk score: a practical tool to predict type 2 diabetes risk. Diabetes Care 26 (2003) 725-731
16. American Diabetes Association. Diabetes Risk Test (2006). http://www.diabetes.org/risk-test.jsp (accessed June 2006)
17. Aekplakorn W., Bunnag P., Woodward M., Sritara P., Cheepudomwit S., Yamwong S., et al. A risk score for predicting incident diabetes in the Thai population. Diabetes Care 29 (2006) 1872-1877
18. Ruige J.B., de Neeling J.N., Kostense P.J., Bouter L.M., and Heine R.J. Performance of an NIDDM screening questionnaire based on symptoms and risk factors. Diabetes Care 20 (1997) 491-496
19. Griffin S.J., Little P.S., Hales C.N., Kinmonth A.L., and Wareham N.J. Diabetes risk score: towards earlier detection of type 2 diabetes in general practice. Diabetes Metab. Res. Rev. 16 (2000) 164-171
20. Glumer C., Carstensen B., Sandbaek A., Lauritzen T., Jorgensen T., and Borch-Johnsen K. A Danish diabetes risk score for targeted screening: the Inter99 study. Diabetes Care 27 (2004) 727-733
21. Rathmann W., Martin S., Haastert B., Icks A., Holle R., Löwel H., et al. Performance of screening questionnaires and risk scores for undiagnosed diabetes: the KORA Survey 2000. Arch. Intern. Med. 165 (2005) 436-441
22. Schulze M., Hoffmann K., Boeing H., Linseisen J., Rohrmann S., Möhlig M., et al. An accurate risk score based on anthropometric, dietary and lifestyle factors to predict teh development of type 2 diabetes. Diabetes Care 30 (2007) 510-515
23. Balkau B., Lange C., Fezeu L., Tichet J., de Lauzon-Guillain B., Czernichow S., et al. Predicti×ng diabetes: clinical, biological, and genetic approaches: data from the Epidemiological Study on the Insulin Resistance Syndrome (DESIR). Diabetes Care 10 (2008) 2056-2061
24. Hippiisley-Cox J., Coupland C., Robson J., Sheikh A., and Brindle P. Predicting risk of type 2 diabetes in England and Whales: prospective derivation and validation. Br. Med. J. 10 (2009) 273-282
25. Herman W.H., Smith P.J., Thompson T.J., Engelgau M.M., and Aubert R.E. A new and simple questionnaire to identify people at increased risk for undiagnosed diabetes. Diabetes Care 18 (1995) 382-387
26. Pearson T.L., Pronk N.P., Tan A.W., and Halstenson C. Identifying individuals at risk for the development of type 2 diabetes mellitus. Am. J. Manag. Care 9 (2003) 57-66
27. Schmidt M.I., Duncan B.B., Bang H., Pankow J.S., Ballantyne C.M., Golden S.H., et al. Identifying individuals at high risk for diabetes: the Atherosclerosis Risk in Communities study. Diabetes Care 28 (2005) 2013-2018
28. Kanaya A.M., Wassel Fyr C.L., de Rekeneire N., Shorr R.I., Schwartz A.V., Goodpaster B.H., et al. Predicting the development of diabetes in older adults: the derivation and validation of a prediction rule. Diabetes Care 28 (2005) 404-408
29. Mohan V., Deepa R., Deepa M., Somannavar S., and Datta M. A simplified Indian Diabetes Risk Score for screening for undiagnosed diabetic subjects. J. Assoc. Physicians India 53 (2005) 759-763
30. Al-Lawati J.A., and Tuomilehto J. Diabetes risk score in Oman: a tool to identify prevalent type 2 diabetes among Arabs of the Middle East. Diabetes Res. Clin. Pract. 77 (2007) 438-444
31. Kahn R., Buse J., Ferrannini E., and Stern M. The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 28 (2005) 2289-2304
32. Unwin N., Shaw J., Zimmet P., and Alberti K.G.M.M. Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. Diabet. Med. 19 (2002) 708-723
33. Lindström J., Ilanne-Parikka P., Peltonen M., Aunola S., Eriksson J.G., Hemiö K., et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet 368 (2006) 1673-1679
34. Lindström J., Peltonen J.M., Eriksson J.G., Aunola S., Hämäläinen H., Ilanne-Parikka P., et al. Determinants for the effectiveness of lifestyle intervention in the Finnish Diabetes Prevention Study. Diabetes Care 31 (2008) 857-862
35. Chiasson J.L., Gomis R., Hanefeld M., Josse R.G., Karasik A., and Laakso M. The STOP-NIDDM trial: an international study on the efficacy of an alpha-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data. Study to Prevent Non-Insulin-Dependent Diabetes Mellitus. Diabetes Care 21 (1998) 1720-1725
36. Chiasson J.L., Josse R.G., Gomis R., Hanefeld M., Karasik A., and Laakso M. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 359 (2002) 2072-2077
37. Chiasson J.L., Josse R.G., Gomis R., Hanefeld M., Karasik A., and Laakso M. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 290 (2003) 486-494
38. Yliharsila H., Lindstrom J., Eriksson J.G., Jousilahti P., Valle T.T., Sundvall J., et al. Prevalence of diabetes and impaired glucose regulation in 45- to 64-year-old individuals in three areas of Finland. Diabet. Med. 22 (2005) 88-91
39. World Health Organization. Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications. Part 1. Diagnosis and Classification of Diabetes mellitus (1999), World Health Organization, Geneva
40. Sullivan L.M., Massaro J.M., and D'Agostino Sr. R.B. Presentation of multivariate data for clinical use: the Framingham Study risk score functions. Stat. Med. 23 (2004) 1631-1660
41. Harrell F.E. Regression Modeling Strategies with Applications to Linear Models, Logistic Regression, and Survival Analysis (2001), Springer, New York
42. Harris M. Undiagnosed NIDDM: clinical and public health issues. Diabetes Care 16 (1993) 642-652
43. Diabetes Prevention Program Research, Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 346 (2002) 393-403
44. Tuomilehto J., Lindström J., Eriksson J.G., Valle T.T., Hämäläinen H., Ilanne-Parikka P., et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N. Engl. J. Med. 344 (2001) 1343-1350
45. Schwarz P.E., Lindström J., Kissimova-Skarbek K., Szybinski Z., Barengo N.C., Peltonen M., et al. The European perspective of type 2 diabetes prevention: diabetes in Europe-prevention using lifestyle. Physical activity and nutritional intervention (DE-PLAN) project. Exp. Clin. Endocrinol. Diabetes 116 (2008) 167-172
46. Schwarz P.E., Gruhl U., Bornstein S.R., Landgraf R., Hall M., and Tuomilehto J. The European perspective on diabetes prevention: development and implementation of A European Guideline and training standards for diabetes prevention (IMAGE). Diab. Vasc. Dis. Res. 4 (2007) 353-357